Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a large decline in short interest in the month of June. As of June 30th, there was short interest totaling 14,925 shares, a decline of 69.0% from the June 15th total of 48,137 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 628,782 shares, the short-interest ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Daiichi Sankyo Price Performance

Shares of DSNKY traded down $0.05 during midday trading on Tuesday, hitting $16.70. The company’s stock had a trading volume of 207,508 shares, compared to its average volume of 406,965. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18. Daiichi Sankyo has a one year low of $14.98 and a one year high of $27.50. The stock has a market capitalization of $31.11 billion, a price-to-earnings ratio of 17.77, a price-to-earnings-growth ratio of 2.94 and a beta of -0.17. The company’s fifty day simple moving average is $16.35 and its two-hundred day simple moving average is $18.15.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its earnings results on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). The business had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, equities analysts expect that Daiichi Sankyo will post 0.98 earnings per share for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.